AstraZeneca fails to quell doubters

Article Abstract:

AstraZeneca plans a major launch for the company's Nexium drug which is to replace Losec. The company faces competition from producers of generic drugs when Losec ceases to be protected by a patent from 2001. Astra's stock price has been volatile. The company aims to deliver over 15 drug candidates annually by 2003. Meanwhile, Novartis and AstraZeneca are to shed their agrochemicals activities to set up Syngenta, a new company, and that affects the policy of developing a life science company.

Management, AstraZeneca PLC

---

Biotech bargains

Article Abstract:

Biotechnology shares have declined since Mar 2000, but careful investors can still make money out of the sector. The risks can be minimised by making sure a firm has adequate funding, has the right management to get drugs through clinical trials and agrees the right licensing deals.

Methods, Biotechnology industry, Biotechnology industries, Portfolio management, Securities

---

Protein age kicks

Article Abstract:

The scientific and research policies of Oxford Glycosciences are examined in detail. The company's research strategy is explained by Raj Parekh, the key figure in this area.

Science and technology policy, Oxford GlycoSciences PLC

Similar abstracts:

• Abstracts: Bank defence fails to impress the City. HBOS signals last act in banking drama. Abbey could rue BoS failure
• Abstracts: Investment banks: first annual survey. Best investment banks. World's best investment banks 2000
• Abstracts: Electronics Boutique. Dixons. Computacenter
• Abstracts: Yielding to second thoughts. So you want to be a day trader. Small numbers, big trouble
• Abstracts: Medical supplies & devices. Investing in health sciences

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.